Journal
CURRENT DRUG DELIVERY
Volume 8, Issue 1, Pages 26-44Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156720111793663651
Keywords
Radioimmunotherapy; radiolabeled antibody; solid tumor; antigen
Categories
Funding
- NCI NIH HHS [P30 CA006973] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of Y-90 ibritumomab tiuxetan (Zevalin) and I-131 Tositumomab (Bexxar) in treating non-Hodgkin's lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available